-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114

Benzinga·10/07/2026 14:23:45
Listen to the news
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.